Human arylamine N-acetyltransferase 1 (NAT1) is a phase II xenobiotic metabolizing enzyme found in almost all tissues. NAT1 can also hydrolyze acetyl-coenzyme A (acetylCoA) in the absence of an arylamine substrate. Expression of NAT1 varies between individuals and is elevated in several cancers including estrogen receptor positive (ER+) breast cancers. To date, however, the exact mechanism by which NAT1 expression affects mitochondrial bioenergetics in breast cancer cells has not been described. To further evaluate the role of NAT1 in energy metabolism MDA-MB-231 breast cancer cells with parental, increased, and knockout levels of NAT1 activity were compared for bioenergetics profile. Basal oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured followed by programmed sequential injection of Oligomycin (ATP synthase inhibitor), FCCP (ETC uncoupler), Antimycin A (Complex III inhibitor), and Rotenone (Complex I inhibitor) to evaluate mitochondrial bioenergetics.
cofactor 4, 5 however the implications of this reaction in metabolism and bioenergetics are undefined (reviewed in ref. 6 ). NAT1 expression varies inter-individually and is commonly elevated in several cancers including estrogen receptor positive (ER+) breast cancers. 7 A 2009 microarray study of 56 breast tumor samples and 10 normal tissue samples revealed NAT1 expression was higher in invasive carcinoma compared with normal tissue. 8, 9 Computational analysis of a previously published microarray dataset containing 89 breast cancer samples also revealed that NAT1 is commonly amplified in breast carcinomas. 10, 11 Comparative proteomic analysis of eight normal breast samples and 25 breast cancer derived tissues demonstrated that NAT1 is elevated in invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) when compared to normal breast tissue. 12 Overexpression of NAT1 in the conditionally immortalized HB4a human mammary luminal epithelial cell line leads to increased cell growth and resistance to the chemotherapeutic etoposide. 12 Additionally, knockdown of NAT1 in the MDA-MB-231 triple negative breast cancer cell line, through both small molecule inhibition and siRNA, leads to decreased cell growth, and metastatic and invasive abilities [13] [14] [15] (reviewed in ref. 16 ). However, the exact mechanism by which NAT1 expression affects breast cancer risk and progression has yet to be described.
Recent studies have demonstrated that congenic rats expressing higher NAT2 (orthologous to human NAT1) activity exhibited more carcinogen-induced mammary tumors, independent of carcinogen metabolism. 17 Notably, endogenous acetyl-CoA was shown to be decreased in MDA-MB-231 cells with increased NAT1 activity when compared to the MDA-MB-231 cell line with parental NAT1 activity. 18 Investigation of the polar metabolome of the same cells also revealed statistically significant differences in a number of metabolites, including amino acids, and palmitoleic acid. 18 These observations, along with NAT1's extensive tissue distribution, 19 presence in nearly every species, 20 and ability to catalyze the hydrolysis of acetyl-CoA, 4 ,5 lead us to hypothesize that NAT1's role in cancer may be related to regulation of acetyl-CoA. Recently, NAT1 was postulated to have an endogenous role in the methionine salvage pathway, but this role was not observed in MDA-MB-231 cells since they do not have a functional methionine salvage pathway due to a lack of methylthioadenosine phosphorylase (MTAP) activity. 21 To further investigate the hypothesis that NAT1 can influence the levels of acetyl-CoA thus leading to downstream effects on mitochondrial bioenergetics, we constructed MDA-MB-231 triple negative breast cancer (TNBC) cell lines that vary only in NAT1 activity. The MDA-MB-231 cell line was chosen because it expresses an approximate midlevel of NAT1 RNA when compared to other breast cancer cell lines. 22 Selecting a single breast cancer cell line and manipulating the level of NAT1 in that single cell line has allowed us to evaluate the effect of both increased and knockout NAT1 expression in a breast cancer cell line model that has the same genetic background. This method eliminates confounding mutations that would be present when using multiple breast cancer cell lines that innately express varying levels of NAT1 thus making interpretations about NAT1's role more straightforward.
As NAT1 has been reported to hydrolyze acetyl-CoA and increased (Up) levels of human arylamine N-acetyltransferase 1 (NAT1) were used as samples. 13, 18 The Scrambled cell line was included as a transfection control. Additionally, newly constructed cell lines expressing no detectable (knockout) NAT1 activity (CRISPR 2-19, CRISPR 5-50) were used as samples ( Figure 1 ). All cell lines, including newly constructed CRISPR/Cas9 generated cell lines, were authenticated by the ATCC Short Tandem Repeat (STR) profiling cell authentication service.
| Construction of CRISPR/Cas9 cell lines
The complete NAT1 knockout cell lines utilized within this study were cloning cylinders were utilized to isolate those colonies using trypsin to release them from the plate and transferred to a 96-well culture plate.
Clones were passaged until there were enough cells to plate in a 10 cm
dish. Cells were then tested for NAT1 activity as previously described. 24 Activity assays showed NAT1 activity was not detectable (knocked out) in a low number of clones and these clones were selected for further characterization. Clones with no detectable NAT1 activity were further screened by sequencing the NAT1 open reading frame (ORF). We were specifically interested in clones that had deleted/inserted nucleotides in the NAT1 ORF that resulted in frameshift mutations and thus premature protein termination signals resulting in predicted nonfunctional NAT1. Individual knockout cell lines representing the knockout of NAT1 activity for gRNA #2 or #5
were chosen based on NAT1 enzymatic activity and genomic sequence. Further details on NAT1 knockout cell line construction and characterization are described elsewhere. well plates and allowed to grow for 5 consecutive days. Cells were plated on day 1 and allowed to equilibrate for 24 h before making the first count on day 2 followed by counts on days 3, 4, 5, and 6 using a cell counter. The cell doubling time was calculated as previously described. 13 This assay was performed in triplicate for each cell line.
| Mitochondrial bioenergetics
The Seahorse XF24 Analyzer (Agilent Technologies, Santa Clara, CA) was utilized to interrogate differences in mitochondrial cellular metabolism via oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) measurements of live cells. All cell lines were cultured in high-glucose Dulbecco's modified Eagle medium (DMEM), with 10% fetal bovine serum, 5% glutamine, and 5% penicillin/ streptomycin added.
Twenty-four hours prior to each bioenergetics experiment, 100 µL of cell suspension from each cell line was plated in quadruplicate in a 24-well Seahorse XF24 cell culture microplate at a density of 40 000 cells per well, thus giving four biological replicates for each cell line. Additionally, four wells contained medium only for background correction purposes. To minimize the edge effects of plating and to ensure a monolayer of cells was formed on the bottom of the well, microplates were left in the cell culture hood at room temperature for 1 h before being placed in a 37°C, 5% CO 2 incubator.
After cells had adhered to the plate (3 h after placing in the incubator), Microplates were then incubated for 1 h in a non-CO 2 37°C incubator.
The XF24 sensor cartridge was hydrated overnight in XF calibrant solution in a non-CO 2 37°C incubator.
Before each experiment, solutions of compounds to be loaded in the ports of the sensor cartridge were freshly made from stock Maximum Mitochondrial Capacity, and Non-Mitochondrial Respiration were calculated as described in Table 1 following each experiment. 26, 27 Results from each independent experiment were summarized as mean ± SEM from four biological replicates on the microplate. Results from all six independent experiments were then compiled with final results represented as mean ± SEM. One-way ANOVA was conducted for each measurement to test for overall differences, followed by multiplicity adjusted post hoc tests on only those measurements that were found to be significant. Patients were split by median into low and high NAT1 expression groups (n = 128 and n = 127, respectively). Hazard ratio (HR), 95%
| MTT cell growth assays
confidence intervals, and logrank P were calculated.
| RESULTS
NAT1 N-acetylation activity was significantly (P < 0.05) higher in the Knockout of NAT1 activity increased reserve capacity and maximum mitochondrial capacity when compared to the cell lines with parental (Parent, Scrambled) and increased (Up) NAT1 activity (P < 0.05 for all; Figure 2 ). In the Parent, Scrambled, and Up cell lines the maximal respiration was lower than the basal OCR measurements resulting in a negative value for the reserve capacity calculation; as reserve capacity cannot be negative biologically, we termed the reserve capacity measurements in these groups as 0. were decreased 1.7-fold with respect to the Parent cell line (P < 0.05). We did not observe an effect of modulation of NAT1 activity on coupling efficiency, also called coupling ratio, which is defined as (oligomycin-sensitive OCR)/(basal OCR) ( Figure 5 ). This result agrees with the data in Figure 3 showing that altering NAT1 activity had no effect on basal OCR or ATP-linked OCR in these cell lines.
Overall, it is important to note that the two cell lines with parental NAT1 activity (Parent, Scrambled) showed comparable results. The knockout of NAT1 in MDA-MB-231 cells led to differences in multiple bioenergetics measurements while the overexpression of NAT1 led to no significant (P > 0.05) differences when compared to the cell lines expressing parental (Parent, Scrambled) NAT1 activity.
To rule out differences in cell growth rate between cell lines over the course of our experiments, an MTT assay was conducted and the equivalence of MTT absorbance values were evaluated.
With the exception of the Parent to Scrambled comparison, there was sufficient evidence to assert equivalence (P < 0.05) in each of the pairwise equivalence tests. The Parent to Scrambled equivalence test was marginally significant (P = 0.065). This data suggests that cell line with a FRT site added into the genome and a scrambled shRNA transfected into that FRT site) was included as a transfection control. 18 We did not observe a significant effect of the scrambled shRNA on cellular bioenergetics in MDA-MB-231 cells. The Up cell line (the Parent MDA-MB-231 cell line with a FRT site added into the genome and a plasmid overexpressing human NAT1 stably transfected into that FRT site) yields overexpression of NAT1. 18 Finally, two complete NAT1 knockout cell lines (CRISPR 2-19 and CRISPR 5-50) constructed using CRISPR/Cas9 technology (as described in the Section 2), were evaluated to verify that observed effects were due to differences in NAT1 as opposed to off-target effects caused by a specific guide-RNA.
Therefore, we have concluded a result was due to the knockout of NAT1 only when the same trend was observed in both CRISPR/Cas9 constructed cell lines. Reserve capacity is the difference between the basal and maximal respiration of the mitochondria and is broadly an evaluation of a cells ability to respond to increased energy demands such as those found in rapidly dividing cancer cells. 30 respond better to these increased energy demands. Here we report that NAT1 knockout, using two guide RNAs, increased the glycolytic reserve in MDA-MB-231 cells. There have been many studies 9, 14, 33, 34 investigating the inhibition of NAT1 with small molecule inhibitors as a possible way to decrease the cancerous and metastatic properties of malignant cells; however, our data suggests knockout of NAT1 may allow cells to increase glycolysis and use mitochondrial reserve.
Mitochondria facilitate cellular stress responses, including the response to hypoxia and the activation of programmed cell death via the release of pro-apoptotic molecules. 35 Differences in mitochondrial function between cells that express varying levels of NAT1 may play a role in cancer initiation or tumorigenesis by modulating these responses.
It appears knockout of NAT1 allows cells to express more plasticity in terms of response to energy demand. Our data suggest that NAT1 may play a role in an unknown response mechanism that keeps cancer cells from hijacking the mitochondrial machinery to produce increased amounts of ATP that would be needed by cancer cells.
In conclusion, we have observed that differences in NAT1 activity, particularly the knockout of NAT1, significantly alters the bioenergetics profile of MDA-MB-231 triple negative breast cancer cells. Reserve capacity, maximal respiration, and glycolytic reserve capacity were increased in the NAT1 knockout cell lines. Increases in these measurements suggest that NAT1 knockout cells may be better able to respond to stress. These findings provide evidence that NAT1mo-difies cellular acetyl-CoA levels and mitochondrial bioenergetics.
Further investigation into the specific role NAT1 is playing in regulating cellular metabolism and bioenergetics is needed, ongoing, and will best be investigated via a multidisciplinary approach.
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